A research team led by Luigi Naldini at SR-Tiget developed a new strategy to make CRISPR-Cas9 genome editing in human hematopoietic stem cells more efficient and safer. The approach is reported to address key barriers that have constrained broader clinical use of genome editing therapies, including precision and risk-control challenges. The work adds to the growing portfolio of next-generation editing platforms that aim to improve intended functional outcomes while reducing unintended effects. HSC editing remains a high-value target area because it can enable one-time treatments for hematologic disorders—if safety hurdles are consistently overcome. For translational teams, the next focus is how the platform performs in relevant in vivo settings and what it means for manufacturing scale, quality control, and regulatory comparability.